Epigenetic modifications in the biology of nonalcoholic fatty liver disease: The role of DNA hydroxymethylation and TET proteins

Medicine (United States)

Volumn 94, Issue 36, 2015, Pages

  Pirola, Carlos J ^a   Scian, Romina ^a   Gianotti, Tomas Fernández ^a   Dopazo, Hernán ^a   Rohr, Cristian ^a   Martino, Julio San ^b   Castaño, Gustavo O ^c   Sookoian, Silvia ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b Hospital Diego Thompson   (Argentina)

^c Hospital General de Agudos Dr Abel Zubizarreta   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; CYTOKERATIN 18; MESSENGER RNA; MITOCHONDRIAL DNA; PEPTIDES AND PROTEINS; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TEN ELEVEN TRANSLOCATION 1 PROTEIN; TEN ELEVEN TRANSLOCATION 2 PROTEIN; TEN ELEVEN TRANSLOCATION 3 PROTEIN; UNCLASSIFIED DRUG; 5-HYDROXYMETHYLCYTOSINE; CYTOSINE; DNA BINDING PROTEIN; HEAT SHOCK PROTEIN; ONCOPROTEIN; PPARGC1A PROTEIN, HUMAN; TET1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ABDOMINAL OBESITY; ADULT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; FEMALE; GENE DOSAGE; GENE LOCUS; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER MITOCHONDRION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MITOCHONDRIAL GENOME; NEXT GENERATION SEQUENCING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; SINGLE NUCLEOTIDE POLYMORPHISM; STEATOSIS; ANALOGS AND DERIVATIVES; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; ORGANELLE BIOGENESIS; PATHOLOGY;

ADULT; CYTOSINE; DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEAT-SHOCK PROTEINS; HUMANS; LIVER; MALE; MIDDLE AGED; MITOCHONDRIA, LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; ORGANELLE BIOGENESIS; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTORS;

EID: 84941686246     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001480     Document Type: Article

References (38)

1. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686-690.
2. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol. 2008;49:600-607.
3. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341-1350.
4. Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab. 2013;98:483-495.
5. Tarantino G, Finelli C. What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome? World J Gastroenterol. 2013;19:3375-3384.
6. Sookoian S, Rosselli MS, Gemma C, et al. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor gamma coactivator 1alpha promoter. Hepatology. 2010;52:1992-2000.
7. Brunt EM. Pathology of fatty liver disease. Mod Pathol. 2007;20(Suppl 1):S40-S48.
8. Brunt EM. Histopathology of non-alcoholic fatty liver disease. Clin Liver Dis. 2009;13:533-544.
9. Fierbinteanu-Braticevici C, Negreanu L, Tarantino G. Is fatty liver always benign and should not consequently be treated? J Physiol Pharmacol. 2013;64:3-9.
10. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13:643-654.
11. Torres DM, Harrison SA. Nonalcoholic fatty liver disease: fibrosis portends a worse prognosis. Hepatology. 2015;61:1462-1464.
12. Sookoian S, Pirola CJ. The genetic epidemiology of nonalcoholic fatty liver disease: toward a personalized medicine. Clin Liver Dis. 2012;16:467-485.
13. Ahrens M, Ammerpohl O, von Schönfels W, et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct diseasespecific and remodeling signatures after bariatric surgery. Cell Metab. 2013;18:296-302.
14. Murphy SK, Yang H, Moylan CA, et al. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145:1076-1087.
15. Pirola CJ, Gianotti TF, Burgueno AL, et al. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut. 2013;62:1356-1363.
16. Caldwell SH, de Freitas LA, Park SH, et al. Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis. Hepatology. 2009;49:1888-1895.
17. Koliaki C, Szendroedi J, Kaul K, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 2015;21:739-746.
18. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183-1192.
19. Song BJ, Akbar M, Abdelmegeed MA, et al. Mitochondrial dysfunction and tissue injury by alcohol, high fat, nonalcoholic substances and pathological conditions through post-translational protein modifications. Redox Biol. 2014;3:109-123.
20. Zeybel M, Hardy T, Robinson SM, et al. Differential DNA methylation of genes involved in fibrosis progression in nonalcoholic fatty liver disease and alcoholic liver disease. Clin Epigenetics. 2015;7:25.
21. Wyatt GR, Cohen SS. A new pyrimidine base from bacteriophage nucleic acids. Nature. 1952;170:1072-1073.
22. Laird A, Thomson JP, Harrison DJ, et al. 5-Hydroxymethylcytosine profiling as an indicator of cellular state. Epigenomics. 2013;5:655-669.
23. Nestor CE, Ottaviano R, Reddington J, et al. Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. Genome Res. 2012;22:467-477.
24. Thomson JP, Hunter JM, Lempiainen H, et al. Dynamic changes in 5-hydroxymethylation signatures underpin early and late events in drug exposed liver. Nucleic Acids Res. 2013;41:5639-5654.
25. Shock LS, Thakkar PV, Peterson EJ, et al. DNA methyltransferase 1, cytosine methylation, and cytosine hydroxymethylation in mammalian mitochondria. Proc Natl Acad Sci USA. 2011;108:3630-3635.
26. Bellizzi D, D'Aquila P, Scafone T, et al. The control region of mitochondrial DNA shows an unusual CpG and non-CpG methylation pattern. DNA Res. 2013;20:537-547.
27. Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324:930-935.
28. Xin YJ, Yuan B, Yu B, et al. Tet1-mediated DNA demethylation regulates neuronal cell death induced by oxidative stress. Sci Rep. 2015;5:7645.
29. Eguchi A, Wree A, Feldstein AE. Biomarkers of liver cell death. J Hepatol. 2014;60:1063-1074.
30. Kleiner DE, Brunt EM, Van NM, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321.
31. Brunt EM, Kleiner DE, Wilson LA, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53:810-820.
32. Skol AD, Scott LJ, Abecasis GR, et al. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet. 2006;38:209-213.
33. Jin C, Lu Y, Jelinek J, et al. TET1 is a maintenance DNA demethylase that prevents methylation spreading in differentiated cells. Nucleic Acids Res. 2014;42:6956-6971.
34. Williams K, Christensen J, Pedersen MT, et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature. 2011;473:343-348.
35. Williams K, Christensen J, Helin K. DNA methylation: TET proteins-guardians of CpG islands? EMBO Rep. 2012;13:28-35.
36. Udali S, Guarini P, Moruzzi S, et al. Global DNA methylation and hydroxymethylation differ in hepatocellular carcinoma and cholangiocarcinoma and relate to survival rate. Hepatology. 2015;62:496-504.
37. Leers MP, Kolgen W, Bjorklund V, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol. 1999;187:567-572.
38. Ivanov M, Kals M, Kacevska M, et al. Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function. Genome Biol. 2013;14:R83.